RecruitingPhase 3NCT06463587
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Principal Investigator
- Medical ResponsibleEMD Serono Research & Development Institute, Inc.
- Intervention
- Placebo(other)
- Enrollment
- 264 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
- Advanced Neurosciences Research LLC, Longmont, Colorado, United States
- The George Washington University Medical Faculty Associates Foggy Bottom South Pavilion, Washington D.C., District of Columbia, United States
- Neurology of Central Florida Research Center, LLC, Altamonte Springs, Florida, United States
- SFM Clinical Research, LLC, Boca Raton, Florida, United States
- University of Florida Health Science Center - 300120311, Jacksonville, Florida, United States
- Neurology Associates, P. A., Maitland, Florida, United States
- University of South Florida - PARENT - PARENT, Tampa, Florida, United States
- University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN), Kansas City, Kansas, United States
- UNC Hospitals - PARENT, Chapel Hill, North Carolina, United States
- Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
- Miami Valley Hospital South, Centerville, Ohio, United States
- Clinical Trials of South Carolina - Charleston, Charleston, South Carolina, United States
- Erlanger Health, Inc. - 1123255, Chattanooga, Tennessee, United States
- Baylor Scott & White Research Institute - Baylor Scott & White Research Institute, Dallas, Texas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
EMD Serono Research & Development Institute, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06463587 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.